Cardiovascular Journal of Africa: Vol 22 No 3 (May/June 2011) - page 5

Reference: 1. Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart
Study): a randomized, open-label, blinded endpoint morbidity-mortality study. The Lancet 2007;369:1431-1439. 2. Jikei Heart Study Available from: URL:http://www.escardio.org/congresses/
World_Congress_Cardiology_2006/Documents/Dahlof-Mochizuki-FP3419-slide-resource-wcc06.pdf. S3 Zomevek
®
80, 160. Reg No:43/7.1.3/0036,7. Each tablet contains 80/160 mg valsar-
tan. S3 Co-Zomevek
®
80/12,5, 160/12.5, 160/25. Reg No: 43/7.1.3/0080,1,2. Each tablet contains 80/160 mg valsartan and 12.5/25 mg hydrochlorothiazide. Marketed by Sandoz SA
(Pty) Ltd. 72 Steel Road, Spartan, Kempton Park, 1619. Tel: 011 929 9000, Fax: 011 929 9296.
Reg No. 1990/001979/07. SAN 1627 09 2010
For further information refer to the package insert
a Novartis company
Beyond Hypertension control
Treatment must consider not only aggressive blood
pressure control, but also which blood pressure
molecule is the best choice to prevent outcomes
1,2
1,2,3,4 6,7,8,9,10,11,12,13,14,15,...60
Powered by FlippingBook